Suppr超能文献

TFR1 介导的铁代谢调控非小细胞肺癌中的肿瘤铁死亡和免疫。

TFR1-Mediated Iron Metabolism Orchestrates Tumor Ferroptosis and Immunity in Non-Small Cell Lung Cancer.

机构信息

Department of Thoracic Surgery, Nanjing Chest Hospital, Nanjing 210029, P.R China.

Department of Thoracic Surgery, People's Hospital of Luhe District in Nanjing, Nanjing 210000, P.R China.

出版信息

J Environ Pathol Toxicol Oncol. 2024;43(2):1-12. doi: 10.1615/JEnvironPatholToxicolOncol.2023049084.

Abstract

This study aimed to investigate the underlying molecular mechanisms of transferrin receptor (TFR1) in non-small cell lung cancer (NSCLC). Histological analysis was performed using hematoxylin-eosin (HE) staining. The number of CD8+ T cell were determined by flow cytometry and immunofluorescence assays. mRNA levels were analyzed by qRT-PCR. Protein expression was detected by western blot. Ferroptosis was detected by using propidium iodide (PI) staining. Xenograft experiment was applied for determining tumor growth. The results showed that interferon (IFN)-γ plus iron dextran (FeDx) induced iron overload and the ferroptosis of NSCLC cells. Moreover, IFN-γ-mediated upregulation of TFR1 promoted ferritinophagy and tumor cell ferroptosis via blocking via blocking ferritin heavy chain 1 (FTH1)/ ferritin light chain (FTL) signaling. However, TFR1 knockout suppressed the ferroptosis of tumor cells. Furthermore, FeDx-mediated iron overload promoted the sensitivity of anti-programmed death ligand 1 (PD-L1) therapies. Clinically, TFR1 was downregulated in NSCLC patients. Low levels of TFR1 predicted decreased CD8+ T cells. Taken together, IFN-γ combined with iron metabolism therapies may provide a novel alternative for NSCLC.

摘要

本研究旨在探讨转铁蛋白受体(TFR1)在非小细胞肺癌(NSCLC)中的潜在分子机制。采用苏木精-伊红(HE)染色进行组织学分析。通过流式细胞术和免疫荧光法测定 CD8+T 细胞的数量。通过 qRT-PCR 分析 mRNA 水平。通过 Western blot 检测蛋白表达。通过碘化丙啶(PI)染色检测铁死亡。应用异种移植实验确定肿瘤生长。结果表明,干扰素(IFN)-γ 加铁右旋糖苷(FeDx)诱导 NSCLC 细胞铁过载和铁死亡。此外,IFN-γ 介导的 TFR1 上调通过阻断铁蛋白重链 1(FTH1)/铁蛋白轻链(FTL)信号促进 ferritinophagy 和肿瘤细胞铁死亡。然而,TFR1 敲除抑制了肿瘤细胞的铁死亡。此外,FeDx 介导的铁过载促进了抗程序性死亡配体 1(PD-L1)治疗的敏感性。临床上,TFR1 在 NSCLC 患者中下调。TFR1 水平低预示着 CD8+T 细胞减少。总之,IFN-γ 联合铁代谢治疗可能为 NSCLC 提供一种新的选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验